基于Oncomine数据库荟萃分析CD24在卵巢癌中的表达和临床意义

目的：探讨CD24在卵巢癌中的表达及意义。方法：收集Oncomine数据库中关于CD24的数据信息，并对目前数据库中资料进行二次分析，对其在卵巢癌中的作用进行统计分析。利用Kaplan-Meier Plotter进行患者生存周期分析。结果：从数据库中纳入不同肿瘤类型研究共计353项，其中64项研究存在CD24表达统计学差异（含高表达研究41项及低表达研究23项）。经过筛选，涉及CD24在正常卵巢组织和卵巢癌组织表达差异的研究共7项（包含5 149例样本），与对照组相比，CD24在367例卵巢癌标本中高表达（P＜0.05）。CD24表达量与卵巢癌总体生存率呈负相关，CD24表达水平越高则患者总体生存率越低（P＜0.05）。进一步亚组分析发现，卵巢子宫内膜样腺癌和卵巢浆液性囊腺癌患者中CD24高表达组的总体生存率较差，而低表达组的总体生存率较好。结论：CD24在卵巢癌组织中高表达，且与卵巢癌预后有关，可能为肿瘤药物的开发提供重要理论依据。

Expression of CD24 and Its Prognostic Role in Ovarian Cancer: An Analysis Based on the Data-Mining of Oncomine Database

Objective：To investigate the expression and clinical value of CD24 in ovarian cancer． Methods: Data about CD24 expression in ovarian cancer were retrieved from the Oncomine database, then the prognostic value of CD24 was retrieved from an online survival analysis tool "Kaplan-Meier Plotter" (KM plotter) database. Results: For different types of cancer in Oncomine, there were 353 studies concerning expression of CD24, of which 64 studies were of statistically significance (41 up-regulated and 23 down-regulated). 5 149 samples of 7 studies assessed the expression of CD24 in ovarian cancer tissues and normal tissues. The expression of CD24 was significantly higher in the ovarian cancer tissue compared with the normal tissues (P＜0.05). And negatively associated with the overall survival rate (P＜0.05). Subgroup analysis revealed that CD24 expression showed negative relation to the prognosis of ovarian endometrioid adenocarcinoma patients and ovarian serous cystadenocarcinoma patients. Conclusions: CD24 is overexpression in ovarian cancer and negatively associated with the overall survival rate, which may be used as an important target of medication for ovarian cancer．